Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Patterns of Spontaneous Adverse Events Reporting on Human Papillomavirus Vaccines according to the Applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017

국내 사람유두종바이러스백신 접종 후 자발적 이상반응 보고사례의 Brighton Collaboration 기준 활용 가능성 연구

  • Received : 2020.01.21
  • Accepted : 2020.03.02
  • Published : 2020.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To describe patterns of spontaneous reporting on adverse events following immunization (AEFIs) using the human papilloma virus (HPV) vaccine according to the Brighton Collaboration (BC) criteria. Methods: We used the Korea Adverse Event Reporting System (KAERS) database including vaccinations between 2008 and 2017. To apply BC criteria, we classified 58 BC AEFIs into World Health Organization Adverse Reaction Terminology (WHO-ART) codes. We applied MedDRA standard medical queries that were pre-defined as five BC AEFIs. Terminology mapping between MedDRA and WHO-ART terms was performed by three researchers. Descriptive statistics of individual case safety reports were analyzed according to BC applicability. Disproportionality analyses were performed on each BC AEFI and each preferred AEFI term according to the case-noncase approach; reporting odds ratio (ROR) and 95% confidence intervals (CI) were calculated. Results: Among the 30,266 reports of vaccinations between 2008 and 2017, 2,845 reports included the HPV vaccine. Of these reports, 1,511 (53.1%) included at least one BC AEFI. Reports from physicians or manufacturers included more BC AEFIs than from other reporters. Injection site reactions and fever were frequently reported in BC AEFIs; spontaneous abortion and ectopic pregnancy (ROR, 14.29 [95% CI, 4.30-47.49]) and vasculitic peripheral neuropathy (ROR, 8.57 [95% CI, 2.61-28.10]) showed the highest ROR. Among non-BC AEFIs, dizziness or myalgia were frequently reported; exposure during pregnancy (ROR, 23.95 [95% CI, 16.27-35.25]) and inappropriate schedule of administration (ROR, 22.89 [95% CI, 16.74-31.31]) showed the highest ROR. Conclusion: BC criteria would be applicable for labeled AEFIs, whereas analyzing non-BC AEFIs would be useful for detecting unlabeled AEFIs.

Keywords

References

  1. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4(1):46-55. https://doi.org/10.1038/nri1260
  2. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine 2017;35(43):5753-5. https://doi.org/10.1016/j.vaccine.2017.05.069
  3. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009;15(1):116-9. https://doi.org/10.1177/1352458508096868
  4. Yonee C, Toyoshima M, Maegaki Y, et al. Association of Acute Cerebellar Ataxia and Human Papilloma Virus Vaccination: A Case Report. Neuropediatrics 2013;44(05):265-7. https://doi.org/10.1055/s-0033-1333873
  5. Tomljenovic L, Shaw C. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental. Pharmaceut Reg Affairs S 2012;12:2.
  6. World Health Organization. Vaccine safety basics e-learning course. Available from https://vaccine-safety-training.org/. Accessed January 21, 2020.
  7. Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance; Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Available from https://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf. Accessed March 24, 2020.
  8. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP); Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinegood-pharmacovigilance-practices-gvp-product-populationspecific-considerations-i-vaccines_en.pdf. Accessed March 24, 2020.
  9. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012;30(11):2020-3. https://doi.org/10.1016/j.vaccine.2011.12.042
  10. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7):750-7. https://doi.org/10.1001/jama.2009.1201
  11. Choe YJ, Cho H, Bae G-R, Lee J-K. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine 2011;29(11):2066-70. https://doi.org/10.1016/j.vaccine.2011.01.007
  12. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 22.1. Available from https://www.meddra.org/sites/default/files/guidance/file/000356_smq_intguide_22_1.pdf. Accessed March 24, 2020.
  13. van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11(1):3-10. https://doi.org/10.1002/pds.668
  14. Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie 2019;74(2):225-32. https://doi.org/10.1016/j.therap.2019.01.006
  15. Scotti L, Romio S, Ghirardi A, et al. Should methods of correction for multiple comparisons be applied in pharmacovigilance? Epidemiol Biostat Public Health 2015;12(4):e11654.
  16. Ministry of Food and Drug Safety. Available from https://nedrug.mfds.go.kr/. Accessed January 20, 2020
  17. Gidudu J, Kohl KS, Halperin S, et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008;26(52):6800-13. https://doi.org/10.1016/j.vaccine.2008.10.006
  18. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003;52(1):1-24.
  19. Enforcement Regulations of the Infectious Disease Control and Prevention Act [Annexed Form No. 2] . Available from http://www.law.go.kr/engLsSc.do?tabMenuId=tab45&query=infectious%20disease%20control%20and%20prevention%20act#. Accessed March 27, 2020.
  20. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 2018;132(1): 35-44. https://doi.org/10.1097/AOG.0000000000002694
  21. Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol 2015;34(7):1225-31. https://doi.org/10.1007/s10067-014-2846-1
  22. Melo Gomes S, Glover M, Malone M, Brogan P. Vasculitis following HPV immunization. Rheumatology 2012;52(3):581-2. https://doi.org/10.1093/rheumatology/kes168
  23. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Noren GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in $VigiBase^{(R)}$. Drug Saf 2017;40(1):81-90. https://doi.org/10.1007/s40264-016-0456-3
  24. Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 2015;33(22):2602-5. https://doi.org/10.1016/j.vaccine.2015.03.098
  25. Kinoshita T, Abe R, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014;53(19):2185-200. https://doi.org/10.2169/internalmedicine.53.3133
  26. World Health Organization. Safety update of HPV vaccines. Available from https://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/. Accessed January 20, 2020.
  27. Korea Centers for Disease Control and Prevention. Available from https://nip.cdc.go.kr/irgd/introduce.do?MnLv1=3&MnLv2=6&MnLv3=3. Accessed January 20, 2020.
  28. Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013. Vaccine 2015;33(28):3171-8. https://doi.org/10.1016/j.vaccine.2015.05.006
  29. Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015;33(29):3422-8. https://doi.org/10.1016/j.vaccine.2015.04.014
  30. Top KA, Constantinescu CM, Lafleche J, et al. Applicability of the Brighton Collaboration case definition for seizure after immunization in active and passive surveillance in Canada. Vaccine 2013;31(48):5700-5. https://doi.org/10.1016/j.vaccine.2013.09.048
  31. Public Health Agency of Canada. Reporting Adverse Events Following Immunization (AEFI) in Canada: User Guide to completion and submission of the AEFI reports 2019. Available from https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/reporting-adverse-events-followingimmunization/user-guide-completion-submission-aefi-reports/aefiuser-guide-jan-22-2020-eng.pdf. Accessed March 2, 2020.
  32. Law BJ, Lafleche J, Ahmadipour N, Anyoti H. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012. Can Commun Dis Rep 2014;40(Suppl 3):7-23.
  33. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18(6):427-36. https://doi.org/10.1002/pds.1742
  34. Chung SY, Jung SY, Shin JY, Park BJ. The role of the KIDS for enhancing drug safety and risk management in Korea. J Korean Med Assoc 2012;55(9):861-8. https://doi.org/10.5124/jkma.2012.55.9.861